Tirzepatide vs Retatrutide: a research comparison

Research use only. This content is for laboratory research; not for human or veterinary use, diagnosis, or treatment.

Producto para uso experimental en laboratorio. No es medicamento ni producto de consumo humano.

Tirzepatide (LY3298176) and retatrutide (LY3437943) are two of the most studied incretin agonists of the past decade. They come from the same research lineage but differ on one decisive point: how many receptors they activate. This comparison summarizes the mechanistic difference as documented in the literature and — most relevant to a lab — how to evaluate and contrast the quality of each compound when sourcing it for research.

What each compound is

Tirzepatide is a dual agonist that activates the GIP and GLP-1 receptors. It is the compound behind Mounjaro® and Zepbound®, and carries the larger body of published clinical literature of the two. Retatrutide is a triple agonist: it adds glucagon-receptor activation to those same GIP and GLP-1 axes, and sits in more recent stages of investigation.

• Tirzepatide (LY3298176): dual GIP / GLP-1 agonist. Mature clinical literature (SURPASS/SURMOUNT programs).
• Retatrutide (LY3437943): triple GIP / GLP-1 / glucagon agonist. More recent published evidence, advanced investigation.

The key mechanistic difference: the third receptor

GLP-1 is associated with satiety and glucose-dependent insulin secretion; GIP with insulin sensitivity and lipid metabolism. Retatrutide adds a third axis — the glucagon receptor — which the literature links to increased energy expenditure and effects on hepatic lipid metabolism. That third receptor is precisely what distinguishes retatrutide from tirzepatide at the molecular-design level.

What the published evidence shows

In retatrutide's phase 2 trial published in the New England Journal of Medicine, the magnitude of the reported outcomes was notable within its study cohort ^[1]. For tirzepatide, the SURMOUNT-1 trial is the heaviest published reference ^[2]. Both are human studies cited here purely as scientific context for the compounds; they are not a usage guide or an administration recommendation.

How to compare quality when sourcing either one

For a lab, the decision is settled by documentation, not marketing. The criteria are identical for both compounds:

1. Lot-specific certificate of analysis (COA) with HPLC (reverse-phase) purity and mass-spectrometry (MS) identity confirmation.
2. Traceability: a lot number and analysis date that map to the vial you received.
3. Endotoxin (LAL) testing where the in-vitro protocol requires it.
4. Documented storage conditions and stability data for the lyophilized material.

How to choose between them for your protocol

If your protocol works on the GIP/GLP-1 axes with the most consolidated literature base, tirzepatide is the option with the larger volume of published data. If the research interest specifically includes the glucagon axis, retatrutide is the triple-design compound. In either case, prioritize the lot with a verifiable COA and documented purity above any other consideration.